Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021
04 nov. 2021 17h34 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Announces Participation in November Conferences
04 nov. 2021 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
01 nov. 2021 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium
07 oct. 2021 07h51 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
05 oct. 2021 16h22 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
01 sept. 2021 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
12 août 2021 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022 Reached agreement with...
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
02 août 2021 08h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
26 juil. 2021 08h00 HE
|
Eledon Pharmaceuticals, Inc.
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501 IRVINE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”)...
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
02 juil. 2021 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...